LYSA – The Lymphoma Study Association
The French-Belgian lymphoma group, successor to GELA, whose LNH-98.5 trial made R-CHOP the standard for diffuse large B-cell lymphoma.
LYSA was formed in 2012 by merging GELA (founded 1984) and GOELAMS; LYSARC is its academic research organisation. GELA's LNH-98.5 was the trial that added rituximab to CHOP and changed the outcome of DLBCL worldwide, and PRIMA established rituximab maintenance in follicular lymphoma. LYSA co-ran POLARIX (polatuzumab-R-CHP) and leads trials of bispecific antibodies, CAR-T sequencing and PET-guided therapy across France, Belgium and Portugal. It maintains a national lymphoma pathology review network (Lymphopath) and the REALYSA real-world cohort.
- LNH-98.5 (R-CHOP)
- PRIMA (rituximab maintenance)
- POLARIX (with Roche)
- REALYSA cohort and Lymphopath
Pages like this
not linked directly; found by shared links- IdeaHead-to-head bispecific vs CAR-T in second-line LBCL
Shares Glofitamab, Axicabtagene ciloleucel, Diffuse large B-cell lymphoma, CAR-T cell therapy.
- InstitutionNordic Lymphoma Group
Shares International Extranodal Lymphoma Study Group, Hodgkin lymphoma, Monoclonal antibodies, Diffuse large B-cell lymphoma.
- InstitutionIRCCS Azienda Ospedaliero-Universitaria di Bologna – Policlinico Sant'Orsola
Shares Glofitamab, Bispecific antibodies, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
- InstitutionHOVON
Shares German Lymphoma Alliance, International Extranodal Lymphoma Study Group, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
- TermLymphoma (tissue type)
Shares Glofitamab, Axicabtagene ciloleucel, Hodgkin lymphoma, Diffuse large B-cell lymphoma.
- InstitutionGerman Hodgkin Study Group
Shares German Lymphoma Alliance, FDG PET, Hodgkin lymphoma.
- InstitutionUniversity Hospital Southampton / Centre for Cancer Immunology
Shares FDG PET, Hodgkin lymphoma, Monoclonal antibodies, Diffuse large B-cell lymphoma.
- TermLugano classification / Ann Arbor staging
Shares FDG PET, Hodgkin lymphoma, Diffuse large B-cell lymphoma.